Objective:
To discuss the relevance of subretinal hyperreflective material (SHRM) to vision and summarize key findings from the TENAYA and LUCERNE studies regarding treatment efficacy.
Key Findings:
- Faricimab shows a greater reduction in SHRM area and volume during the loading phase compared to aflibercept, suggesting improved treatment efficacy.
- The amount of SHRM present at 12 weeks predicts vision outcomes over time, reinforcing the need for early intervention.
Interpretation:
Eliminating SHRM early is crucial for improving vision outcomes, supporting the use of second-generation agents like faricimab, which demonstrate superior resolution of SHRM.
Limitations:
Conclusion:
The findings underscore the importance of targeting SHRM for better visual outcomes in patients, advocating for the adoption of effective treatment strategies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
